RxDoctor Payments Data

Donna Meneeley

Nurse Practitioner · Bethlehem, PANPI 1336114180

Payments from drug & device makers

$1,396in general payments, 2019–2025

Across 14 payments — averaging $99.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$329
  • Esperion Therapeutics, Inc.$242
  • Lilly USA, LLC$240
  • AbbVie$125
  • Amgen$125
  • Phathom Pharmaceuticals, Inc.$125
  • plus $210 from 3 others

What the payments were for

  • Food & beverage$1,396100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,396 in reported general payments places this provider in the 85th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$84,365
Medicare patients
215
Services billed
1,482

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide68$121,156
EliquisApixaban53$45,636
JardianceEmpagliflozin49$44,337
MounjaroTirzepatide21$28,090
Tresiba Flextouch U-200Insulin Degludec13$15,498
JanuviaSitagliptin Phosphate14$10,194
XareltoRivaroxaban15$9,853
TrintellixVortioxetine Hydrobromide11$5,165
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$3,139
Albuterol Sulfate HfaAlbuterol Sulfate111$2,452
Levothyroxine Sodium243$2,383
SynthroidLevothyroxine Sodium47$2,208
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp11$2,188
Novolog FlexpenInsulin Aspart16$2,144
Atorvastatin Calcium258$2,086

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$20$121,15668 claims
Boehringer IngelheimJardiance$125$44,33749 claims
Lilly USA, LLCMounjaro$240$28,09021 claims
AbbVieSynthroid$125$2,20847 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Bethlehem

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →